FDA approval of exenatide, its first generic injectable GLP-1 agonist, Amneal (2024) Teva announces FDA approval and launch of generic Saxenda (liraglutide injection) first generic GLP-1 indicated for weight loss, Teva Pharmaceuticals (2025) Exenatide, DailyMed (2025) Byetta, DailyMed (2025) Liraglutide (generic Victoza), DailyMed (2025) Liraglutide (generic Saxenda), DailyMed (2025) Victoza, DailyMed (2025) Saxenda, DailyMed (2025) Compounding and the FDA: Questions and answers, U.S
Exenatide was first made available for type 2 diabetes management in 2005 as Byetta, a twice-daily injection
Plus, GLP-1s carry the risk of side effects like nausea, vomiting and diarrhea
It is given as a weekly self-injection
Aqu estn los consejos de Wyatt para el mantenimiento del peso